Aigen Investment Management LP Purchases Shares of 5,948 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Aigen Investment Management LP purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,948 shares of the company’s stock, valued at approximately $685,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GSA Capital Partners LLP grew its holdings in shares of Neurocrine Biosciences by 441.3% during the 3rd quarter. GSA Capital Partners LLP now owns 8,682 shares of the company’s stock worth $1,000,000 after purchasing an additional 7,078 shares during the period. Los Angeles Capital Management LLC grew its holdings in shares of Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of Neurocrine Biosciences by 16.5% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 8,487 shares of the company’s stock worth $978,000 after purchasing an additional 1,204 shares during the period. Sigma Planning Corp purchased a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $230,000. Finally, Covestor Ltd grew its holdings in shares of Neurocrine Biosciences by 11.5% during the 3rd quarter. Covestor Ltd now owns 1,779 shares of the company’s stock worth $205,000 after purchasing an additional 183 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Barclays decreased their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Oppenheimer upped their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Jefferies Financial Group upped their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday. Finally, BMO Capital Markets dropped their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Stock Down 1.2 %

Shares of NBIX stock opened at $125.51 on Thursday. The stock has a 50-day simple moving average of $118.47 and a 200 day simple moving average of $132.93. Neurocrine Biosciences, Inc. has a fifty-two week low of $107.84 and a fifty-two week high of $157.98. The stock has a market capitalization of $12.71 billion, a P/E ratio of 33.65 and a beta of 0.35.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.